Phase IV, National, Unicentric, Comparative, Double-Blind, Randomized, Non- Inferiority Clinical Trial to Evaluate the Efficacy and Safety of DNN.22.17.036 Compared to 10573048700 in the Treatment of Androgenetic Alopecia (CAPELLI)

NCT06355856 Phase 4 UNKNOWN

Evaluation of the efficacy and safety of DNN.22.17.036 versus 10573048700 in the treatment of male pattern hair loss.

Details

Lead sponsor	Ache Laboratorios Farmaceuticos S.A.
Phase	Phase 4
Status	UNKNOWN
Enrolment	196
Start date	2024-04
Completion	2025-05

Conditions

• Alopecia

Interventions

• DNN.22.17.036
• 10573048700

Primary outcomes

• Percentage variation of hairs in the hair loss phase — 180 days
  Percentage variation of hairs in the hair loss phase (telogen hairs), by image analysis with the FotoFinder Leviacam®, after 180 days of treatment.